Intelligent Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins
Rhea-AI Summary
Intelligent Bio Solutions (Nasdaq: INBS) announced a strategic manufacturing partnership with Syrma Johari MedTech to scale production of its Intelligent Fingerprinting Drug Screening Reader ahead of planned U.S. market entry in 2026.
The collaboration is expected to deliver >40% annual production cost savings, an ~20 percentage‑point improvement in gross margin versus the prior arrangement, and ~4x current manufacturing capacity through Syrma Johari’s 14 facilities and 1.1M+ sq ft footprint. Syrma Johari holds ISO 13485, MDSAP, FDA, TUV SUD, and GMP certifications to support global regulatory needs.
Positive
- Annual production cost savings of >40% stated
- Gross margin expected to improve ~20 percentage points
- Manufacturing capacity ~4x INBS’ current capacity
- Syrma Johari operates 14 facilities and 1.1M+ sq ft
Negative
- None.
News Market Reaction – INBS
On the day this news was published, INBS gained 132.44%, reflecting a significant positive market reaction. Argus tracked a peak move of +180.1% during that session. Our momentum scanner triggered 116 alerts that day, indicating very high trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $12M at that time. Trading volume was exceptionally heavy at 2305.2x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Within Medical Devices peers, moves are mixed: AIMD -9.09%, NXL -8.64%, ALUR -2.33%, while NVNO +1.15% and SINT +0.8%. Only one momentum peer (PAVM +8.09%) screened higher, suggesting today’s INBS catalyst is stock-specific rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Strategic partnership | Positive | +18.4% | Non-exclusive alliance with Vlepis to expand non-invasive and wearable screening. |
| Dec 12 | Reverse stock split | Neutral | -22.7% | 1-for-10 reverse split to address Nasdaq minimum bid price compliance. |
| Nov 20 | Conference participation | Neutral | -6.3% | Participation in Noble Capital Markets emerging growth equity conference. |
| Nov 12 | Earnings results | Positive | -1.7% | Record fiscal Q1 2026 revenue, margin gains, and customer/account growth. |
| Nov 04 | Preliminary revenue | Positive | -9.1% | Pre-announced record Q1 revenue with strong YoY and sequential growth. |
Recent history shows multiple positive operational and growth updates, yet the stock often moved negatively or modestly afterward, with only one clear positive alignment on partnership news.
Over the last few months, Intelligent Bio Solutions reported record fiscal Q1 2026 revenue of $1,111,797, growing both sequentially and year-over-year, and highlighted margin expansion and new customer wins. It also pre-announced record revenue, added 33 new customer accounts, and participated in an investor conference. Corporate actions included a 1‑for‑10 reverse stock split to address Nasdaq bid-price compliance. A recent strategic partnership with Vlepis on non-invasive screening drove a strong positive price reaction. Today’s manufacturing partnership continues this theme of operational scaling and global expansion.
Regulatory & Risk Context
The company has an active S-3/A shelf dated 2025-08-25. The prospectus excerpt describes Series J warrants with an initial exercise price of $1.90 per share, exercisable into up to 4,046,456 common shares upon stockholder approval. The shelf is noted as not yet effective and has at least one related 424B5 usage filing on 2025-09-18.
Market Pulse Summary
The stock surged +132.4% in the session following this news. A strong positive reaction aligns with management’s emphasis on scaling and margin expansion. The Syrma Johari partnership targets production cost savings of more than 40% and an expected 20‑point gross margin uplift, building on prior revenue growth and partnership-driven expansion. However, an active S-3/A shelf with Series J warrants and past dilutive financings could influence future supply dynamics, so investors have historically balanced enthusiasm for growth with capital-structure risk.
Key Terms
gross margin financial
ISO 13485 regulatory
MDSAP regulatory
FDA regulatory
GMP regulatory
clean-room technical
AI-generated analysis. Not financial advice.
Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS’ global manufacturing capacity, strengthens supply-chain resilience, and supports an expected improvement of approximately 20 percentage points in gross margin ahead of planned U.S. market entry
NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new strategic manufacturing partnership with Syrma Johari MedTech Ltd. (“Syrma Johari”), a globally recognized medical device engineering and manufacturing organization with over 45 years of experience, to support and scale the production of its Intelligent Fingerprinting Drug Screening Reader. The collaboration is also expected to support long-term margin improvement.
The partnership is expected to deliver significant operational and financial benefits for the Company. INBS anticipates annual production cost savings of more than
The partnership strengthens INBS' global manufacturing strategy, reducing reliance on a single supplier and building greater resilience into its supply chain. It further broadens capacity, ensures continuity, and creates flexibility as the Company prepares for anticipated future demand across multiple regions and planned U.S. market entry in 2026.
Syrma Johari brings a deep and proven track record in the design, engineering, and production of regulated medical technology devices. It operates 14 manufacturing locations and four design and innovation centres across India, Europe, and the United States, with a combined plant area of over 1.1 million sq. ft. Syrma Johari is fully certified to ISO 13485, MDSAP, FDA, TUV SUD, and GMP standards, ensuring world-class compliance and quality in medical device manufacturing.
Syrma Johari’s scale, vertical integration, and export-oriented operating model enable high-quality production while creating efficiencies in sourcing, tooling, testing, and logistics. Its expertise in electronics, mechanical assembly, PCB manufacturing, functional testing, and clean-room processes positions them to produce INBS' fingerprint drug-screening reader to a consistently high standard, while delivering cost advantages over time. As Syrma Johari prepares to open its new medical-grade plastics manufacturing facility in India in January 2026, it is further expanding its capabilities to meet growing global demand and provide international clients with a strategically located, reliable manufacturing alternative in Asia.
Syrma Johari’s extensive regulatory and quality-assurance capabilities further align with INBS' global expansion plans. It provides end-to-end quality systems, regulatory documentation support, and compliance processes designed to meet the requirements of major jurisdictions, including the U.S., Europe, Canada, the UK, and key Asia-Pacific markets. This depth of experience will support INBS as it continues advancing its regulatory pathways and prepares for increased commercial activity worldwide.
“Partnering with Syrma Johari is a strategically significant milestone for our business,” said Callistus Sequeira, Vice President of Global Quality and Operations at Intelligent Bio Solutions. “Its global footprint, manufacturing excellence, and proven track record in regulated medical devices make it an outstanding partner as we scale production of our Drug Screening Reader. This collaboration strengthens our supply chain, supports future growth, and enhances our ability to deliver reliable, high-quality products to customers around the world.”
Syrma Johari’s leadership shared a similar sentiment, noting that the partnership reflects a strong alignment in innovation, quality, and long-term vision, and that it is pleased to support INBS in scaling a disruptive drug-screening technology with global potential.
“Partnering with Intelligent Bio Solutions is an exciting opportunity to apply our engineering strength, manufacturing scale, and quality systems to a breakthrough technology with global potential,” said Pankaj Wadke, Head International Sales & Business Development at Syrma Johari MedTech Ltd. “At Syrma Johari MedTech, we are committed to enabling innovative solutions that make a meaningful impact, and we look forward to supporting INBS as they expand access to this disruptive, non-invasive drug-screening platform.”
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: https://ibs.inc/
About Syrma Johari MedTech
Syrma Johari MedTech is a global medical device engineering and manufacturing company with over 45 years of experience delivering advanced electronics, medical devices, and life-science equipment. Operating 14 manufacturing facilities and multiple R&D centres across India, the U.S., and Europe, the company provides end-to-end services spanning design, engineering, prototyping, PCBA, assembly, supply chain, and QARA support. Syrma Johari holds ISO 13485:2016, MDSAP, FDA, GMP, and TUV SUD certifications and has commercialised 245+ medical products worldwide.
For more information, visit: https://syrmajoharimedtech.com/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
What cost savings did INBS announce with Syrma Johari (INBS)?
How much will INBS' gross margin change after the Syrma Johari deal?
How does Syrma Johari’s capacity compare to INBS’ current capacity for INBS products?
Will the Syrma Johari partnership support INBS’ U.S. market entry timeline?
What quality and regulatory standards does Syrma Johari hold relevant to INBS (INBS)?
